Is BDTX or OCGN more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% Ocugen N/A -127,987.80% -115.95%

Does the media refer more to BDTX or OCGN?

In the previous week, Ocugen had 19 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 24 mentions for Ocugen and 5 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.14 beat Ocugen's score of -0.22 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocugen 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PBYI or BDTX?

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for Black Diamond Therapeutics and 4 mentions for Puma Biotechnology. Black Diamond Therapeutics' average media sentiment score of 1.14 beat Puma Biotechnology's score of 0.58 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Black Diamond Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, LRMR or BDTX?

Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Larimar Therapeutics N/A N/A -$165.67M -$1.95 N/A Black Diamond Therapeutics N/A N/A $22.37M -$0.75 N/A

Is LRMR or BDTX more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -137.39% -97.65% Black Diamond Therapeutics N/A -32.10% -25.21%

Does the media prefer LRMR or BDTX?

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 5 mentions for Black Diamond Therapeutics and 4 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.74 beat Black Diamond Therapeutics' score of 1.14 indicating that Larimar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Black Diamond Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, BDTX or RZLT?

Rezolute is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Diamond Therapeutics N/A N/A $22.37M -$0.75 N/A Rezolute N/A N/A -$74.41M -$0.82 N/A

Is BDTX or RZLT more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% Rezolute N/A -58.82% -54.48%

Does the media refer more to BDTX or RZLT?

In the previous week, Black Diamond Therapeutics had 3 more articles in the media than Rezolute. MarketBeat recorded 5 mentions for Black Diamond Therapeutics and 2 mentions for Rezolute. Rezolute's average media sentiment score of 1.81 beat Black Diamond Therapeutics' score of 1.14 indicating that Rezolute is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rezolute 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, BDTX or CABA?

Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Diamond Therapeutics N/A N/A $22.37M -$0.75 N/A Cabaletta Bio N/A N/A -$167.86M -$1.57 N/A

Is BDTX or CABA more profitable?

Black Diamond Therapeutics' return on equity of -32.10% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% Cabaletta Bio N/A -153.30% -108.14%

Does the media favor BDTX or CABA?

In the previous week, Cabaletta Bio had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 6 mentions for Cabaletta Bio and 5 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.14 beat Cabaletta Bio's score of 0.90 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Diamond Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Black Diamond Therapeutics (BDTX) Competitors

$2.02 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.04 +0.02 (+0.99%)

As of 08/14/2026 07:34 PM Eastern

Compare

BDTX vs. OCGN, PBYI, LRMR, RZLT, and CABA

Should you buy Black Diamond Therapeutics stock or one of its competitors? Black Diamond Therapeutics's main competitors and comparable companies include Ocugen (OCGN), Puma Biotechnology (PBYI), Larimar Therapeutics (LRMR), Rezolute (RZLT), and Cabaletta Bio (CABA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Black Diamond Therapeutics compare to Ocugen?

Black Diamond Therapeutics (NASDAQ:BDTX) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Black Diamond Therapeutics has a beta of 3.28, meaning that its share price is 228% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 4.0% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Ocugen had 19 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 24 mentions for Ocugen and 5 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.14 beat Ocugen's score of -0.22 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ocugen	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Black Diamond Therapeutics presently has a consensus price target of $9.80, indicating a potential upside of 385.15%. Ocugen has a consensus price target of $9.50, indicating a potential upside of 603.70%. Given Ocugen's higher possible upside, analysts plainly believe Ocugen is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Black Diamond Therapeutics' return on equity of -32.10% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Ocugen	N/A	-127,987.80%	-115.95%

Black Diamond Therapeutics has higher earnings, but lower revenue than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.75	N/A
Ocugen	$4.58M	99.93	-$67.85M	-$0.26	N/A

Summary

Black Diamond Therapeutics beats Ocugen on 10 of the 14 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Puma Biotechnology presently has a consensus target price of $6.00, indicating a potential downside of 32.05%. Black Diamond Therapeutics has a consensus target price of $9.80, indicating a potential upside of 385.15%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Puma Biotechnology has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.28, suggesting that its share price is 228% more volatile than the broader market.

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for Black Diamond Therapeutics and 4 mentions for Puma Biotechnology. Black Diamond Therapeutics' average media sentiment score of 1.14 beat Puma Biotechnology's score of 0.58 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Black Diamond Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Puma Biotechnology has a net margin of 11.50% compared to Black Diamond Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 20.76% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	11.50%	20.76%	13.22%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

Puma Biotechnology has higher revenue and earnings than Black Diamond Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	2.00	$31.11M	$0.52	16.98
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.75	N/A

Summary

Puma Biotechnology beats Black Diamond Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 4.0% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Larimar Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.28, suggesting that its stock price is 228% more volatile than the broader market.

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than Larimar Therapeutics. MarketBeat recorded 5 mentions for Black Diamond Therapeutics and 4 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.74 beat Black Diamond Therapeutics' score of 1.14 indicating that Larimar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Black Diamond Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Black Diamond Therapeutics' return on equity of -32.10% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-137.39%	-97.65%
Black Diamond Therapeutics	N/A	-32.10%	-25.21%

Larimar Therapeutics presently has a consensus target price of $11.67, suggesting a potential upside of 167.58%. Black Diamond Therapeutics has a consensus target price of $9.80, suggesting a potential upside of 385.15%. Given Black Diamond Therapeutics' higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Larimar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.75	N/A

Summary

Black Diamond Therapeutics beats Larimar Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Rezolute?

Black Diamond Therapeutics (NASDAQ:BDTX) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Rezolute is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.75	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

In the previous week, Black Diamond Therapeutics had 3 more articles in the media than Rezolute. MarketBeat recorded 5 mentions for Black Diamond Therapeutics and 2 mentions for Rezolute. Rezolute's average media sentiment score of 1.81 beat Black Diamond Therapeutics' score of 1.14 indicating that Rezolute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rezolute	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Black Diamond Therapeutics' return on equity of -32.10% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Rezolute	N/A	-58.82%	-54.48%

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 14.8% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Black Diamond Therapeutics has a beta of 3.28, indicating that its share price is 228% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Black Diamond Therapeutics currently has a consensus price target of $9.80, indicating a potential upside of 385.15%. Rezolute has a consensus price target of $9.38, indicating a potential upside of 103.80%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Rezolute	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Black Diamond Therapeutics beats Rezolute on 10 of the 12 factors compared between the two stocks.

How does Black Diamond Therapeutics compare to Cabaletta Bio?

Black Diamond Therapeutics (NASDAQ:BDTX) and Cabaletta Bio (NASDAQ:CABA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

Black Diamond Therapeutics' return on equity of -32.10% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Cabaletta Bio	N/A	-153.30%	-108.14%

Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.75	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.57	N/A

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Black Diamond Therapeutics has a beta of 3.28, meaning that its share price is 228% more volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.3, meaning that its share price is 230% more volatile than the broader market.

Black Diamond Therapeutics presently has a consensus target price of $9.80, suggesting a potential upside of 385.15%. Cabaletta Bio has a consensus target price of $15.33, suggesting a potential upside of 457.58%. Given Cabaletta Bio's higher possible upside, analysts clearly believe Cabaletta Bio is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Cabaletta Bio had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 6 mentions for Cabaletta Bio and 5 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.14 beat Cabaletta Bio's score of 0.90 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Diamond Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Black Diamond Therapeutics beats Cabaletta Bio on 9 of the 13 factors compared between the two stocks.

Get Black Diamond Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BDTX vs. The Competition

Export

Metric	Black Diamond Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$116.06M	$3.72B	$7.04B	$13.06B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-2.69	10.67	268.81	25.28
Price / Sales	N/A	1,237.76	576.79	76.27
Price / Cash	3.83	102.88	70.48	50.90
Price / Book	1.21	16.78	12.91	6.24
Net Income	$22.37M	-$13.32M	$3.45B	$347.60M
7 Day Performance	3.59%	1.77%	1.11%	1.06%
1 Month Performance	11.60%	1.16%	1.33%	0.81%
1 Year Performance	-26.81%	54.22%	62.44%	20.90%

Black Diamond Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BDTX Black Diamond Therapeutics	2.6175 of 5 stars	$2.02 flat	$9.80 +385.1%	-27.6%	$116.06M	N/A	N/A	90	News Coverage Positive News
OCGN Ocugen	1.8041 of 5 stars	$1.35 -0.4%	$9.50 +606.3%	+31.1%	$456.10M	$4.41M	N/A	80	Analyst Upgrade Analyst Revision
PBYI Puma Biotechnology	1.0676 of 5 stars	$8.70 -0.2%	$6.00 -31.0%	+66.0%	$448.84M	$231.24M	16.72	200	News Coverage Analyst Upgrade
LRMR Larimar Therapeutics	4.0783 of 5 stars	$4.31 +0.8%	$12.57 +192.0%	+2.3%	$446.17M	N/A	N/A	30	Positive News
RZLT Rezolute	2.8417 of 5 stars	$4.62 +0.3%	$9.38 +103.1%	-28.8%	$444.38M	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BDTX) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. OCGN, PBYI, LRMR, RZLT, and CABA

How does Black Diamond Therapeutics compare to Ocugen?

Summary

How does Black Diamond Therapeutics compare to Puma Biotechnology?

Summary

How does Black Diamond Therapeutics compare to Larimar Therapeutics?

Summary

How does Black Diamond Therapeutics compare to Rezolute?

Summary

How does Black Diamond Therapeutics compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Black Diamond Therapeutics (BDTX) Competitors

BDTX vs. OCGN, PBYI, LRMR, RZLT, and CABA

How does Black Diamond Therapeutics compare to Ocugen?

Which has more risk & volatility, BDTX or OCGN?

Do insiders & institutionals believe in BDTX or OCGN?

Does the media refer more to BDTX or OCGN?

Do analysts recommend BDTX or OCGN?

Is BDTX or OCGN more profitable?

Which has better earnings & valuation, BDTX or OCGN?

Summary

How does Black Diamond Therapeutics compare to Puma Biotechnology?

Do analysts rate PBYI or BDTX?

Do insiders and institutionals believe in PBYI or BDTX?

Which has more volatility and risk, PBYI or BDTX?

Does the media prefer PBYI or BDTX?

Is PBYI or BDTX more profitable?

Which has preferable earnings & valuation, PBYI or BDTX?

Summary

How does Black Diamond Therapeutics compare to Larimar Therapeutics?

Do insiders & institutionals hold more shares of LRMR or BDTX?

Which has more volatility & risk, LRMR or BDTX?

Does the media prefer LRMR or BDTX?

Is LRMR or BDTX more profitable?

Do analysts rate LRMR or BDTX?

Which has stronger earnings & valuation, LRMR or BDTX?

Summary

How does Black Diamond Therapeutics compare to Rezolute?

Which has preferable earnings and valuation, BDTX or RZLT?

Does the media refer more to BDTX or RZLT?

Is BDTX or RZLT more profitable?

Do institutionals and insiders believe in BDTX or RZLT?

Which has more risk and volatility, BDTX or RZLT?

Do analysts rate BDTX or RZLT?

Summary

How does Black Diamond Therapeutics compare to Cabaletta Bio?

Is BDTX or CABA more profitable?

Which has preferable earnings and valuation, BDTX or CABA?

Do institutionals & insiders hold more shares of BDTX or CABA?

Which has more risk & volatility, BDTX or CABA?

Do analysts recommend BDTX or CABA?

Does the media favor BDTX or CABA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDTX vs. The Competition

Black Diamond Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools